Manon van Engeland

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6201139/publications.pdf

Version: 2024-02-01

128 papers	11,802 citations	41344 49 h-index	27406 106 g-index
129 all docs	129 docs citations	129 times ranked	17113 citing authors

#	Article	IF	Citations
1	Differential Orthopedia Homeobox expression in pulmonary carcinoids is associated with changes in <scp>DNA</scp> methylation. International Journal of Cancer, 2022, 150, 1987-1997.	5.1	4
2	Molecular pathways in post-colonoscopy versus detected colorectal cancers: results from a nested caseâ€“control study. British Journal of Cancer, 2022, 126, 865-873.	6.4	6
3	Evaluation of a seven gene mutational profile as a prognostic factor in a population-based study of clear cell renal cell carcinoma. Scientific Reports, 2022, 12, 6478.	3.3	1
4	Technical considerations in PCR-based assay design for diagnostic DNA methylation cancer biomarkers. Clinical Epigenetics, 2022, 14, 56.	4.1	5
5	Genetic Profiling of Colorectal Carcinomas of Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2022, , .	1.9	2
6	Lessons from a systematic literature search on diagnostic DNA methylation biomarkers for colorectal cancer: how to increase research value and decrease research waste. Clinical and Translational Gastroenterology, 2022, Publish Ahead of Print, .	2.5	1
7	Diagnostic DNA Methylation Biomarkers for Renal Cell Carcinoma: A Systematic Review. European Urology Oncology, 2021, 4, 215-226.	5.4	12
8	Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies. Molecular Oncology, 2021, 15, 901-914.	4.6	7
9	Identification of DNA methylation markers for early detection of CRC indicates a role for nervous system-related genes in CRC. Clinical Epigenetics, 2021, 13, 80.	4.1	22
10	SOX17 expression and its downâ€regulation by promoter methylation in cervical adenocarcinoma in situ and adenocarcinoma. Histopathology, 2020, 76, 383-393.	2.9	15
11	Past, Present and Future of Epigenetics in Adrenocortical Carcinoma. Cancers, 2020, 12, 1218.	3.7	21
12	Switches of SOX17 and SOX2 expression in the development of squamous metaplasia and squamous intraepithelial lesions of the uterine cervix. Cancer Medicine, 2020, 9, 6330-6343.	2.8	8
13	Germline polymorphisms in the Von Hippel-Lindau and Hypoxia-inducible factor 1-alpha genes, gene-environment and gene-gene interactions and renal cell cancer. Scientific Reports, 2020, 10, 137.	3.3	5
14	Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review. Breast Cancer Research, 2020, 22, 13.	5.0	29
15	The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study. Diagnostic and Prognostic Research, 2019, 3, 20.	1.8	1
16	Gene Promoter Methylation in Endometrial Carcinogenesis. Pathology and Oncology Research, 2019, 25, 659-667.	1.9	8
17	Analysis of DNA methylation in cancer: location revisited. Nature Reviews Clinical Oncology, 2018, 15, 459-466.	27.6	486
18	Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review. Clinical Epigenetics, 2018, 10, 35.	4.1	38

#	Article	IF	Citations
19	Cost-effectiveness of High-performance Biomarker TestsÂvsÂFecal Immunochemical Test for Noninvasive ColorectalÂCancer Screening. Clinical Gastroenterology and Hepatology, 2018, 16, 504-512.e11.	4.4	36
20	A combined literature and in silico analysis enlightens the role of the NDRG family in the gut. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 2140-2151.	2.4	11
21	Epigenetics in renal cell cancer: mechanisms and clinical applications. Nature Reviews Urology, 2018, 15, 430-451.	3.8	115
22	Promoter CpG island methylation in ion transport mechanisms and associated dietary intakes jointly influence the risk of clear-cell renal cell cancer. International Journal of Epidemiology, 2017, 46, dyw266.	1.9	18
23	Details matter: the role of genomic location and assay standardization in DNA methylation analyses. Epigenomics, 2017, 9, 933-935.	2.1	5
24	Assessing opportunities for coordinated <scp>R</scp>&<scp>D</scp> in early cancer detection and management in <scp>E</scp>urope. International Journal of Cancer, 2017, 140, 1700-1701.	5.1	1
25	Prognostic DNA methylation markers for renal cell carcinoma: a systematic review. Epigenomics, 2017, 9, 1243-1257.	2.1	44
26	Molecular stool testing as an alternative for surveillance colonoscopy: a cross-sectional cohort study. BMC Cancer, 2017, 17, 116.	2.6	37
27	A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients. Clinical Cancer Research, 2017, 23, 2006-2018.	7.0	51
28	Energy restriction at young age, genetic variants in the insulinâ€like growth factor pathway and colorectal cancer risk in the Netherlands Cohort Study. International Journal of Cancer, 2017, 140, 272-284.	5.1	5
29	Lifestyle, Diet, and Colorectal Cancer Risk According to (Epi)genetic Instability: Current Evidence and Future Directions of Molecular Pathological Epidemiology. Current Colorectal Cancer Reports, 2017, 13, 455-469.	0.5	91
30	Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. Oncotarget, 2017, 8, 63140-63154.	1.8	19
31	The emerging role of GATA transcription factors in development and disease. Expert Reviews in Molecular Medicine, 2016, 18, e3.	3.9	172
32	Alcohol and Dietary Folate Intake and Promoter CpG Island Methylation in Clear-Cell Renal Cell Cancer. Nutrition and Cancer, 2016, 68, 1097-1107.	2.0	9
33	Potential role of gene-environment interactions in ion transport mechanisms in the etiology of renal cell cancer. Scientific Reports, 2016, 6, 34262.	3.3	7
34	Analysis of RET promoter CpG island methylation using methylation-specific PCR (MSP), pyrosequencing, and methylation-sensitive high-resolution melting (MS-HRM): impact on stage II colon cancer patient outcome. Clinical Epigenetics, 2016, 8, 44.	4.1	18
35	Genetic Variants in the Insulin-like Growth Factor Pathway and Colorectal Cancer Risk in the Netherlands Cohort Study. Scientific Reports, 2015, 5, 14126.	3.3	16
36	Spectrin Repeat Containing Nuclear Envelope 1 and Forkhead Box Protein E1 Are Promising Markers for the Detection of Colorectal Cancer in Blood. Cancer Prevention Research, 2015, 8, 157-164.	1.5	29

#	Article	IF	Citations
37	Polymorphisms in genes of the reninâ€angiotensinâ€aldosterone system and renal cell cancer risk: Interplay with hypertension and intakes of sodium, potassium and fluid. International Journal of Cancer, 2015, 136, 1104-1116.	5.1	44
38	Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome. Clinical Cancer Research, 2015, 21, 3492-3500.	7.0	50
39	Formalin-fixed, paraffin-embedded (FFPE) tissue epigenomics using Infinium HumanMethylation450 BeadChip assays. Laboratory Investigation, 2015, 95, 833-842.	3.7	40
40	Mitochondrial DNA copy number in colorectal cancer: between tissue comparisons, clinicopathological characteristics and survival. Carcinogenesis, 2015, 36, bgv151.	2.8	36
41	Prognostic Significance of Promoter Hypermethylation and Diminished Gene Expression of SYNPO2 in Melanoma. Journal of Investigative Dermatology, 2015, 135, 2328-2331.	0.7	13
42	Methylation of RASSF10 promotes cell proliferation and serves as a docetaxel resistant marker in human breast cancer. Discovery Medicine, 2015, 20, 261-71.	0.5	3
43	CHFR Promoter Methylation Indicates Poor Prognosis in Stage II Microsatellite Stable Colorectal Cancer. Clinical Cancer Research, 2014, 20, 3261-3271.	7.0	29
44	Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients. Molecular Oncology, 2014, 8, 679-688.	4.6	33
45	MEN1Gene Mutation and Reduced Expression Are Associated With Poor Prognosis in Pulmonary Carcinoids. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E374-E378.	3.6	62
46	Dietary acrylamide intake and the risk of colorectal cancer with specific mutations in KRAS and APC. Carcinogenesis, 2014, 35, 1032-1038.	2.8	31
47	Promoter CpG Island Hypermethylation in Dysplastic Nevus and Melanoma: CLDN11 as an Epigenetic Biomarker for Malignancy. Journal of Investigative Dermatology, 2014, 134, 2957-2966.	0.7	38
48	Body Size, Physical Activity, Early-Life Energy Restriction, and Associations with Methylated Insulin-like Growth Factorâ€“Binding Protein Genes in Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1852-1862.	2.5	22
49	Chordoma: the entity. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 655-669.	7.4	47
50	Epigenetics in radiotherapy: Where are we heading?. Radiotherapy and Oncology, 2014, 111, 168-177.	0.6	43
51	The mTOR Pathway and the Role of Energy Balance Throughout Life in Colorectal Cancer Etiology and Prognosis: Unravelling Mechanisms Through a Multidimensional Molecular Epidemiologic Approach. Current Nutrition Reports, 2013, 2, 19-26.	4.3	19
52	The CpG Island Methylator Phenotype: What's in a Name?. Cancer Research, 2013, 73, 5858-5868.	0.9	154
53	Promoter methylation of Wnt-antagonists in polypoid and nonpolypoid colorectal adenomas. BMC Cancer, 2013, 13, 603.	2.6	23
54	Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. Cancer and Metastasis Reviews, 2013, 33, 161-71.	5.9	30

#	Article	IF	Citations
55	Frequent Inactivation of Cysteine Dioxygenase Type 1 Contributes to Survival of Breast Cancer Cells and Resistance to Anthracyclines. Clinical Cancer Research, 2013, 19, 3201-3211.	7.0	77
56	An exploration of pathways involved in lung carcinoid progression using gene expression profiling. Carcinogenesis, 2013, 34, 2726-2737.	2.8	49
57	Tracking the Molecular Features of Nonpolypoid Colorectal Neoplasms: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2013, 108, 1042-1056.	0.4	45
58	Dietary heme iron and the risk of colorectal cancer with specific mutations in KRAS and APC. Carcinogenesis, 2013, 34, 2757-2766.	2.8	57
59	Molecular markers and the future of colorectal cancer screening. Colorectal Cancer, 2013, 2, 95-97.	0.8	0
60	Physical Activity, Occupational Sitting Time, and Colorectal Cancer Risk in the Netherlands Cohort Study. American Journal of Epidemiology, 2013, 177, 514-530.	3.4	60
61	CD44 and OTP Are Strong Prognostic Markers for Pulmonary Carcinoids. Clinical Cancer Research, 2013, 19, 2197-2207.	7.0	77
62	Chromosome 5q Loss in Colorectal Flat Adenomas. Clinical Cancer Research, 2012, 18, 4560-4569.	7.0	30
63	Body size and risk for colorectal cancers showing BRAF mutations or microsatellite instability: a pooled analysis. International Journal of Epidemiology, 2012, 41, 1060-1072.	1.9	65
64	DNA Methylation of Phosphatase and Actin Regulator 3 Detects Colorectal Cancer in Stool and Complements FIT. Cancer Prevention Research, 2012, 5, 464-472.	1.5	46
65	Promoter CpG island methylation markers in colorectal cancer: the road ahead. Epigenomics, 2012, 4, 179-194.	2.1	38
66	Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection. Cellular Oncology (Dordrecht), 2012, 35, 309-315.	4.4	25
67	Comprehensive Mutation Analysis in Colorectal Flat Adenomas. PLoS ONE, 2012, 7, e41963.	2.5	20
68	Epigenetic Changes in Basal Cell Carcinoma Affect SHH and WNT Signaling Components. PLoS ONE, 2012, 7, e51710.	2.5	38
69	The adenoma hunt in colorectal cancer screening: defining the target. Journal of Pathology, 2012, 226, 1-6.	4.5	30
70	The CpG island methylator phenotype in colorectal cancer: Progress and problems. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 77-85.	7.4	89
71	Taxane resistance in breast cancer: A closed HER2 circuit?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 197-206.	7.4	22
72	Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 89-102.	7.4	46

#	Article	IF	Citations
73	Colorectal Cancer Epigenetics: Complex Simplicity. Journal of Clinical Oncology, 2011, 29, 1382-1391.	1.6	180
74	A Let-7 MicroRNA SNP in the KRAS 3â€²UTR Is Prognostic in Early-Stage Colorectal Cancer. Clinical Cancer Research, 2011, 17, 7723-7731.	7.0	106
75	Body Size, Physical Activity and Risk of Colorectal Cancer with or without the CpG Island Methylator Phenotype (CIMP). PLoS ONE, 2011, 6, e18571.	2.5	64
76	Molecular Tests for Colorectal Cancer Screening. Clinical Colorectal Cancer, 2011, 10, 8-23.	2.3	90
77	Body Size and Colorectal Cancer Risk After 16.3 Years of Follow-up: An Analysis From the Netherlands Cohort Study. American Journal of Epidemiology, 2011, 174, 1127-1139.	3.4	43
78	Analysis of Promoter CpG Island Hypermethylation in Cancer: Location, Location, Location!. Clinical Cancer Research, 2011, 17, 4225-4231.	7.0	121
79	Dietary methyl donors, methyl metabolizing enzymes, and epigenetic regulators: dietâ€“gene interactions and promoter CpG island hypermethylation in colorectal cancer. Cancer Causes and Control, 2011, 22, 1-12.	1.8	37
80	Characteristics of triple-negative breast cancer. Journal of Cancer Research and Clinical Oncology, 2011, 137, 183-192.	2.5	225
81	Alcohol consumption, alcohol dehydrogenase 1C (ADH1C) genotype, and risk of colorectal cancer in the Netherlands Cohort Study on diet and cancer. Alcohol, 2011, 45, 217-225.	1.7	14
82	Genomic and Epigenomic Integration Identifies a Prognostic Signature in Colon Cancer. Clinical Cancer Research, 2011, 17, 1535-1545.	7.0	136
83	Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma. Epigenetics, 2011, 6, 1047-1052.	2.7	23
84	Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors. Modern Pathology, 2011, 24, 463-470.	5.5	29
85	Test Performance of Immunologic Fecal Occult Blood Testing and Sigmoidoscopy Compared with Primary Colonoscopy Screening for Colorectal Advanced Adenomas. Cancer Prevention Research, 2011, 4, 1563-1571.	1.5	40
86	Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition?. BMC Cancer, 2010, 10, 180.	2.6	45
87	VHL and HIF signalling in renal cell carcinogenesis. Journal of Pathology, 2010, 221, 125-138.	4.5	258
88	The Nâ€myc downstream regulated gene (NDRG) family: diverse functions, multiple applications. FASEB Journal, 2010, 24, 4153-4166.	0.5	249
89	Viewing the Epigenetics of Colorectal Cancer through the Window of Folic Acid Effects. Cancer Prevention Research, 2010, 3, 1509-1512.	1.5	10
90	Childhood and adolescent energy restriction and subsequent colorectal cancer risk: results from the Netherlands Cohort Study. International Journal of Epidemiology, 2010, 39, 1333-1344.	1.9	51

#	Article	IF	Citations
91	Prognostic Significance of Gremlin1 (GREM1) Promoter CpG Island Hypermethylation in Clear Cell Renal Cell Carcinoma. American Journal of Pathology, 2010, 176, 575-584.	3.8	66
92	Early Life Exposure to Famine and Colorectal Cancer Risk: A Role for Epigenetic Mechanisms. PLoS ONE, 2009, 4, e7951.	2.5	104
93	GATA4 and GATA5 are Potential Tumor Suppressors and Biomarkers in Colorectal Cancer. Clinical Cancer Research, 2009, 15, 3990-3997.	7.0	166
94	Prostate Cancer Detected by Methylated Gene Markers in Histopathologically Cancer-Negative Tissues from Men with Subsequent Positive Biopsies. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2717-2722.	2.5	42
95	N-Myc Downstream-Regulated Gene 4 (NDRG4): A Candidate Tumor Suppressor Gene and Potential Biomarker for Colorectal Cancer. Journal of the National Cancer Institute, 2009, 101, 916-927.	6.3	180
96	Genetic Variants of Methyl Metabolizing Enzymes and Epigenetic Regulators: Associations with Promoter CpG Island Hypermethylation in Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 3086-3096.	2.5	78
97	Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21. Carcinogenesis, 2009, 30, 1041-1048.	2.8	46
98	Methylation ofTFPI2in Stool DNA: A Potential Novel Biomarker for the Detection of Colorectal Cancer. Cancer Research, 2009, 69, 4691-4699.	0.9	204
99	Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene. Cellular Oncology, 2009, 31, 371-82.	1.9	12
100	Genetics and epigenetics of renal cell cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1785, 133-155.	7.4	110
101	An Inactivating Mutation in HDAC2 Leads to Dysregulation of Apoptosis Mediated by APAF1. Gastroenterology, 2008, 135, 1654-1664.e2.	1.3	50
102	Associations of dietary methyl donor intake with MLH1 promoter hypermethylation and related molecular phenotypes in sporadic colorectal cancer. Carcinogenesis, 2008, 29, 1765-1773.	2.8	89
103	Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations. Carcinogenesis, 2008, 29, 434-439.	2.8	59
104	Genetic and Epigenetic Alterations in the von Hippel-Lindau Gene: the Influence on Renal Cancer Prognosis. Clinical Cancer Research, 2008, 14, 782-787.	7.0	65
105	Alcohol Consumption and Mutations or Promoter Hypermethylation of thevon Hippelâ€“LindauGene in Renal Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3543-3550.	2.5	9
106	Dietary Folate, Methionine, Riboflavin, and Vitamin B-6 and Risk of Sporadic Colorectal Cancer. Journal of Nutrition, 2008, 138, 2372-2378.	2.9	80
107	Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response. Pharmacogenomics, 2008, 9, 1903-1916.	1.3	23
108	Lamin A/C Is a Risk Biomarker in Colorectal Cancer. PLoS ONE, 2008, 3, e2988.	2.5	186

#	Article	IF	Citations
109	Identification of Epigenetically Silenced Genes in Tumor Endothelial Cells. Cancer Research, 2007, 67, 4138-4148.	0.9	126
110	Comparing the DNA Hypermethylome with Gene Mutations in Human Colorectal Cancer. PLoS Genetics, 2007, 3, e157.	3.5	307
111	Dietary Folate Intake in Combination with MTHFR C677T Genotype and Promoter Methylation of Tumor Suppressor and DNA Repair Genes in Sporadic Colorectal Adenomas. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 327-333.	2.5	43
112	Dual targeting of epigenetic therapy in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2007, 1775, 76-91.	7.4	85
113	Dietary Folate and APC Mutations in Sporadic Colorectal Cancer. Journal of Nutrition, 2006, 136, 3015-3021.	2.9	22
114	TP53 overexpression in recurrent endometrial carcinoma. Gynecologic Oncology, 2006, 100, 397-404.	1.4	28
115	Angiostatic activity of DNA methyltransferase inhibitors. Molecular Cancer Therapeutics, 2006, 5, 467-475.	4.1	93
116	Epigenetic Regulation of Tumor Endothelial Cell Anergy: Silencing of Intercellular Adhesion Molecule-1 by Histone Modifications. Cancer Research, 2006, 66, 10770-10777.	0.9	139
117	Dietary folate intake and k-ras mutations in sporadic colon and rectal cancer in the Netherlands Cohort Study. International Journal of Cancer, 2005, 114, 824-830.	5.1	23
118	Differential Gene Expression in Ovarian Tumors Reveals Dusp 4 and Serpina 5 As Key Regulators for Benign Behavior of Serous Borderline Tumors. Journal of Clinical Oncology, 2005, 23, 7257-7264.	1.6	82
119	CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis, 2005, 26, 1152-1156.	2.8	81
120	APC mutations in sporadic colorectal carcinomas from The Netherlands Cohort Study. Carcinogenesis, 2004, 25, 1219-1226.	2.8	73
121	Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nature Genetics, 2004, 36, 417-422.	21.4	976
122	GATA-4 and GATA-5 Transcription Factor Genes and Potential Downstream Antitumor Target Genes Are Epigenetically Silenced in Colorectal and Gastric Cancer. Molecular and Cellular Biology, 2003, 23, 8429-8439.	2.3	234
123	K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene, 2002, 21, 3792-3795.	5.9	168
124	A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nature Genetics, 2002, 31, 141-149.	21.4	820
125	Annexin V-Affinity assay: A review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry, 1998, 31, 1-9.	1.8	1,567
126	The Effect of the Cyclin-Dependent Kinase Inhibitor Olomoucine on Cell Cycle Kinetics. Experimental Cell Research, 1997, 236, 4-15.	2.6	103

#	Article	IF	Citations
127	Plasma Membrane Alterations and Cytoskeletal Changes in Apoptosis. Experimental Cell Research, 1997, 235, 421-430.	2.6	176
128	A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry, 1996, 24, 131-139.	1.8	451